{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,25]],"date-time":"2026-06-25T04:40:26Z","timestamp":1782362426544,"version":"3.54.5"},"reference-count":69,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,8,5]],"date-time":"2022-08-05T00:00:00Z","timestamp":1659657600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,8,5]],"date-time":"2022-08-05T00:00:00Z","timestamp":1659657600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100004359","name":"Vetenskapsr\u00e5det","doi-asserted-by":"publisher","award":["2019-01088"],"award-info":[{"award-number":["2019-01088"]}],"id":[{"id":"10.13039\/501100004359","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004047","name":"Karolinska Institutet","doi-asserted-by":"publisher","award":["Senior Researcher Award"],"award-info":[{"award-number":["Senior Researcher Award"]}],"id":[{"id":"10.13039\/501100004047","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010663","name":"H2020 European Research Council","doi-asserted-by":"publisher","award":["MegaALS No. 802091"],"award-info":[{"award-number":["MegaALS No. 802091"]}],"id":[{"id":"10.13039\/100010663","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000030","name":"Centers for Disease Control and Prevention","doi-asserted-by":"publisher","award":["1 R01TS000324-01-00"],"award-info":[{"award-number":["1 R01TS000324-01-00"]}],"id":[{"id":"10.13039\/100000030","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100013278","name":"EU Joint Programme \u2013 Neurodegenerative Disease Research","doi-asserted-by":"publisher","award":["2021-00696"],"award-info":[{"award-number":["2021-00696"]}],"id":[{"id":"10.13039\/100013278","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Med"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>Studying whether medications act as potential risk factors for amyotrophic lateral sclerosis (ALS) can contribute to the understanding of disease etiology as well as the identification of novel therapeutic targets. Therefore, we conducted a systematic review to summarize the existing evidence on the association between medication use and the subsequent ALS risk.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>A systematic review was conducted in Medline, Embase, and Web of Science from the date of database establishment to December 10, 2021. References of identified articles were further searched for additional relevant articles. Studies were included if (1) published in English, (2) explored medication use as exposure and development of ALS as outcome, and (3) the design was a human observational study. Clinical trials, reviews, comments, editorials, and case reports were excluded. Quality assessment was performed using a pre-validated tool for non-randomized studies, the Newcastle\u2013Ottawa Assessment Scale (NOS).<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Of the 4760 studies identified, 25 articles, including 13 case\u2013control studies, five nested case\u2013control studies, six cohort studies, and one retrospective chart review, were included in the review. Among these studies, there were 22 distinct study populations that included 171,407 patients with ALS, seven classes of medication examined, and 23 studies with a NOS\u2009\u2265\u20095. There was a general lack of agreement between studies on the associations of cholesterol-lowering drugs, anti-inflammatory drugs, immunosuppressants, antibiotics, oral contraceptives (OCs) or hormone replacement therapy (HRT), antihypertensive drugs, antidiabetics, and drugs for psychiatric and neurological disorders with the subsequent risk of ALS. However, it appeared that statins, aspirin, OCs\/HRT, antihypertensives, and antidiabetics were unlikely related to a higher risk of ALS. The positive associations noted for antibiotics, antidepressants, and skeletal muscle relaxants might be attributable to prodromal symptoms of ALS.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>There is currently no strong evidence to link any medication use with ALS risk.<\/jats:p><\/jats:sec>","DOI":"10.1186\/s12916-022-02442-w","type":"journal-article","created":{"date-parts":[[2022,8,5]],"date-time":"2022-08-05T00:02:29Z","timestamp":1659657749000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Medication use and risk of amyotrophic lateral sclerosis\u2014a systematic review"],"prefix":"10.1186","volume":"20","author":[{"given":"Can","family":"Cui","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiangwei","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyla A.","family":"McKay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline","family":"Ingre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fang","family":"Fang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,8,5]]},"reference":[{"issue":"2","key":"2442_CR1","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1159\/000448921","volume":"47","author":"C Weil","year":"2016","unstructured":"Weil C, Zach N, Rishoni S, Shalev V, Chodick G. Epidemiology of amyotrophic lateral sclerosis: a population-based study in Israel. Neuroepidemiology. 2016;47(2):76\u201381.","journal-title":"Neuroepidemiology"},{"issue":"12","key":"2442_CR2","first-page":"1563","volume":"52","author":"CL Shoesmith","year":"2006","unstructured":"Shoesmith CL, Strong MJ. Amyotrophic lateral sclerosis: update for family physicians. Can Fam Physician. 2006;52(12):1563\u20139.","journal-title":"Can Fam Physician"},{"issue":"5","key":"2442_CR3","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1097\/WCO.0000000000000730","volume":"32","author":"E Longinetti","year":"2019","unstructured":"Longinetti E, Fang F. Epidemiology of amyotrophic lateral sclerosis: an update of recent literature. Curr Opin Neurol. 2019;32(5):771\u20136.","journal-title":"Curr Opin Neurol"},{"issue":"1","key":"2442_CR4","doi-asserted-by":"publisher","first-page":"57","DOI":"10.5152\/tao.2019.4058","volume":"57","author":"AA Sel\u00e7uk","year":"2019","unstructured":"Sel\u00e7uk AA. A Guide for Systematic Reviews: PRISMA. Turk Arch Otorhinolaryngol. 2019;57(1):57\u20138.","journal-title":"Turk Arch Otorhinolaryngol"},{"key":"2442_CR5","volume-title":"The Newcastle-Ottawa scale for theassessment of the quality of nonrandomized studies in metanalyses","author":"GA Wells","year":"2009","unstructured":"Wells GA, Shea B, O\u2019Connell D, Peterson J, Welch V, Losos M, Tugwell P. The Newcastle-Ottawa scale for theassessment of the quality of nonrandomized studies in metanalyses. 2009. (http:\/\/www.ohri.ca\/programs\/clinical_epidemiology\/oxford.asp)."},{"issue":"3\u20134","key":"2442_CR6","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1080\/21678421.2019.1682613","volume":"21","author":"RM Pfeiffer","year":"2020","unstructured":"Pfeiffer RM, Mayer B, Kuncl RW, Check DP, Cahoon EK, Rivera DR, et al. Identifying potential targets for prevention and treatment of amyotrophic lateral sclerosis based on a screen of medicare prescription drugs. Amyotroph Lateral Scler Frontotemporal Degener. 2020;21(3\u20134):235\u201345.","journal-title":"Amyotroph Lateral Scler Frontotemporal Degener"},{"issue":"4","key":"2442_CR7","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1161\/CIRCOUTCOMES.110.936278","volume":"3","author":"HT S\u00f8rensen","year":"2010","unstructured":"S\u00f8rensen HT, Riis AH, Lash TL, Pedersen L. Statin use and risk of amyotrophic lateral sclerosis and other motor neuron disorders. Circ Cardiovasc Qual Outcomes. 2010;3(4):413\u20137.","journal-title":"Circ Cardiovasc Qual Outcomes"},{"issue":"6","key":"2442_CR8","doi-asserted-by":"publisher","first-page":"638","DOI":"10.1136\/jnnp.2010.236752","volume":"82","author":"NA Sutedja","year":"2011","unstructured":"Sutedja NA, van der Schouw YT, Fischer K, Sizoo EM, Huisman MH, Veldink JH, et al. Beneficial vascular risk profile is associated with amyotrophic lateral sclerosis. J Neurol Neurosurg Psychiatr. 2011;82(6):638\u201342.","journal-title":"J Neurol Neurosurg Psychiatr"},{"issue":"10","key":"2442_CR9","doi-asserted-by":"publisher","first-page":"1949","DOI":"10.1007\/s00415-014-7445-1","volume":"261","author":"M Seelen","year":"2014","unstructured":"Seelen M, van Doormaal PT, Visser AE, Huisman MH, Roozekrans MH, de Jong SW, et al. Prior medical conditions and the risk of amyotrophic lateral sclerosis. J Neurol. 2014;261(10):1949\u201356.","journal-title":"J Neurol"},{"issue":"7\u20138","key":"2442_CR10","doi-asserted-by":"publisher","first-page":"538","DOI":"10.1080\/21678421.2018.1511731","volume":"19","author":"DM Freedman","year":"2018","unstructured":"Freedman DM, Kuncl RW, Cahoon EK, Rivera DR, Pfeiffer RM. Relationship of statins and other cholesterol-lowering medications and risk of amyotrophic lateral sclerosis in the US elderly. Amyotroph Lateral Scler Frontotemporal Degener. 2018;19(7\u20138):538\u201346.","journal-title":"Amyotroph Lateral Scler Frontotemporal Degener"},{"issue":"1","key":"2442_CR11","doi-asserted-by":"crossref","first-page":"e12108","DOI":"10.1002\/trc2.12108","volume":"6","author":"G Torrandell-Haro","year":"2020","unstructured":"Torrandell-Haro G, Branigan GL, Vitali F, Geifman N, Zissimopoulos JM, Brinton RD. Statin therapy and risk of Alzheimer\u2019s and age-related neurodegenerative diseases. Alzheimers Dement (N Y). 2020;6(1):e12108.","journal-title":"Alzheimers Dement (N Y)"},{"issue":"6","key":"2442_CR12","doi-asserted-by":"publisher","first-page":"1010","DOI":"10.1111\/ene.14190","volume":"27","author":"D Mariosa","year":"2020","unstructured":"Mariosa D, Kamel F, Bellocco R, Ronnevi LO, Almqvist C, Larsson H, et al. Antidiabetics, statins and the risk of amyotrophic lateral sclerosis. Eur J Neurol. 2020;27(6):1010\u20136.","journal-title":"Eur J Neurol"},{"issue":"5","key":"2442_CR13","doi-asserted-by":"publisher","first-page":"756","DOI":"10.1097\/EDE.0000000000001384","volume":"32","author":"N Skajaa","year":"2021","unstructured":"Skajaa N, Bakos I, Horvath-Puho E, Henderson VW, Lash TL, Sorensen HT. Statin Initiation and risk of amyotrophic lateral sclerosis: a Danish population-based cohort study. Epidemiology. 2021;32(5):756\u201362.","journal-title":"Epidemiology"},{"issue":"3","key":"2442_CR14","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1080\/17482960601179456","volume":"8","author":"RA Popat","year":"2007","unstructured":"Popat RA, Tanner CM, van den Eeden SK, Bernstein AL, Bloch DA, Leimpeter A, et al. Effect of non-steroidal anti-inflammatory medications on the risk of amyotrophic lateral sclerosis. Amyotroph Lateral Scler. 2007;8(3):157\u201363.","journal-title":"Amyotroph Lateral Scler"},{"issue":"6","key":"2442_CR15","doi-asserted-by":"publisher","first-page":"573","DOI":"10.3109\/17482968.2012.703209","volume":"13","author":"E Fondell","year":"2012","unstructured":"Fondell E, O\u2019Reilly \u00c9J, Fitzgerald KC, Falcone GJ, McCullough ML, Thun MJ, et al. Non-steroidal anti-inflammatory drugs and amyotrophic lateral sclerosis: results from five prospective cohort studies. Amyotroph Lateral Scler. 2012;13(6):573\u20139.","journal-title":"Amyotroph Lateral Scler"},{"issue":"2","key":"2442_CR16","doi-asserted-by":"publisher","first-page":"172","DOI":"10.2188\/jea.JE20140070","volume":"25","author":"CP Tsai","year":"2015","unstructured":"Tsai CP, Lin FC, Lee JK, Lee CT. Aspirin use associated with amyotrophic lateral sclerosis: a total population-based case-control study. J Epidemiol. 2015;25(2):172\u20137.","journal-title":"J Epidemiol"},{"issue":"8","key":"2442_CR17","doi-asserted-by":"publisher","first-page":"1763","DOI":"10.1007\/s00415-017-8564-2","volume":"264","author":"T Kuczmarski","year":"2017","unstructured":"Kuczmarski T, Stommel EW, Riley K, Tandan R, Chaudhry V, Clawson L, et al. Medical history of chemotherapy or immunosuppressive drug treatment and risk of amyotrophic lateral sclerosis (ALS). J Neurol. 2017;264(8):1763\u20137.","journal-title":"J Neurol"},{"issue":"11","key":"2442_CR18","doi-asserted-by":"publisher","first-page":"1355","DOI":"10.1111\/ene.13986","volume":"26","author":"J Sun","year":"2019","unstructured":"Sun J, Zhan Y, Mariosa D, Larsson H, Almqvist C, Ingre C, et al. Antibiotics use and risk of amyotrophic lateral sclerosis in Sweden. Eur J Neurol. 2019;26(11):1355\u201361.","journal-title":"Eur J Neurol"},{"issue":"3","key":"2442_CR19","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1159\/000095550","volume":"27","author":"RA Popat","year":"2006","unstructured":"Popat RA, Van Den Eeden SK, Tanner CM, Bernstein AL, Bloch DA, Leimpeter A, et al. Effect of reproductive factors and postmenopausal hormone use on the risk of amyotrophic lateral sclerosis. Neuroepidemiology. 2006;27(3):117\u201321.","journal-title":"Neuroepidemiology"},{"key":"2442_CR20","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1186\/1471-2377-12-25","volume":"12","author":"P Doyle","year":"2012","unstructured":"Doyle P, Brown A, Beral V, Reeves G, Green J. Incidence of and risk factors for motor neurone disease in UK women: a prospective study. BMC Neurol. 2012;12:25.","journal-title":"BMC Neurol"},{"issue":"12","key":"2442_CR21","doi-asserted-by":"publisher","first-page":"1283","DOI":"10.1212\/WNL.0000000000004390","volume":"89","author":"JPK Rooney","year":"2017","unstructured":"Rooney JPK, Visser AE, D\u2019Ovidio F, Vermeulen R, Beghi E, Chio A, et al. A case-control study of hormonal exposures as etiologic factors for ALS in women: Euro-MOTOR. Neurology. 2017;89(12):1283\u201390.","journal-title":"Neurology"},{"issue":"7","key":"2442_CR22","doi-asserted-by":"publisher","first-page":"2130","DOI":"10.1007\/s00415-020-09799-z","volume":"267","author":"K Diekmann","year":"2020","unstructured":"Diekmann K, Kuzma-Kozakiewicz M, Piotrkiewicz M, Gromicho M, Grosskreutz J, Andersen PM, et al. Impact of comorbidities and co-medication on disease onset and progression in a large German ALS patient group. J Neurol. 2020;267(7):2130\u201341.","journal-title":"J Neurol"},{"issue":"1","key":"2442_CR23","doi-asserted-by":"crossref","first-page":"e12174","DOI":"10.1002\/trc2.12174","volume":"7","author":"YJ Kim","year":"2021","unstructured":"Kim YJ, Soto M, Branigan GL, Rodgers K, Brinton RD. Association between menopausal hormone therapy and risk of neurodegenerative diseases: Implications for precision hormone therapy. Alzheimers Dement. 2021;7(1):e12174.","journal-title":"Alzheimers Dement"},{"issue":"1","key":"2442_CR24","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1001\/jamaneurol.2014.3367","volume":"72","author":"FC Lin","year":"2015","unstructured":"Lin FC, Tsai CP, Kuang-Wu Lee J, Wu MT, Tzu-Chi LC. Angiotensin-converting enzyme inhibitors and amyotrophic lateral sclerosis risk: a total population-based case-control study. JAMA Neurol. 2015;72(1):40\u20138.","journal-title":"JAMA Neurol"},{"issue":"5\u20136","key":"2442_CR25","doi-asserted-by":"publisher","first-page":"385","DOI":"10.3109\/21678421.2016.1143515","volume":"17","author":"C Franchi","year":"2016","unstructured":"Franchi C, Bianchi E, Pupillo E, Poloni M, Nobili A, Fortino I, et al. Angiotensin-converting enzyme inhibitors and motor neuron disease: An unconfirmed association. Amyotroph Lateral Scler Frontotemporal Degener. 2016;17(5\u20136):385\u20138.","journal-title":"Amyotroph Lateral Scler Frontotemporal Degener"},{"issue":"1","key":"2442_CR26","doi-asserted-by":"publisher","first-page":"13371","DOI":"10.1038\/s41598-020-70373-8","volume":"10","author":"H Cetin","year":"2020","unstructured":"Cetin H, Sun J, Almqvist C, Reichardt B, Tomschik M, Zimprich F, et al. No association between proton pump inhibitor use and ALS risk: a nationwide nested case\u2013control study. Sci Rep. 2020;10(1):13371.","journal-title":"Sci Rep"},{"issue":"6","key":"2442_CR27","doi-asserted-by":"publisher","first-page":"1003","DOI":"10.1016\/j.neuro.2006.03.015","volume":"27","author":"ER Garwood","year":"2006","unstructured":"Garwood ER, Bekele W, McCulloch CE, Christine CW. Amphetamine exposure is elevated in Parkinson\u2019s disease. Neurotoxicology. 2006;27(6):1003\u20136.","journal-title":"Neurotoxicology"},{"issue":"24","key":"2442_CR28","doi-asserted-by":"publisher","first-page":"2271","DOI":"10.1212\/WNL.0000000000002671","volume":"86","author":"E Roos","year":"2016","unstructured":"Roos E, Mariosa D, Ingre C, Lundholm C, Wirdefeldt K, Roos PM, et al. Depression in amyotrophic lateral sclerosis. Neurology. 2016;86(24):2271\u20137.","journal-title":"Neurology"},{"key":"2442_CR29","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/j.pnpbp.2016.06.006","volume":"71","author":"JM Prosser","year":"2016","unstructured":"Prosser JM, Fieve RR. Patients receiving lithium therapy have a reduced prevalence of neurological and cardiovascular disorders. Prog Neuropsychopharmacol Biol Psychiatry. 2016;71:39\u201344.","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"issue":"1","key":"2442_CR30","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1159\/000448618","volume":"47","author":"F D\u2019Ovidio","year":"2016","unstructured":"D\u2019Ovidio F, d\u2019Errico A, Farina E, Calvo A, Costa G, Chi\u00f2 A. Amyotrophic lateral sclerosis incidence and previous prescriptions of drugs for the nervous system. Neuroepidemiology. 2016;47(1):59\u201366.","journal-title":"Neuroepidemiology"},{"issue":"4","key":"2442_CR31","doi-asserted-by":"publisher","first-page":"688","DOI":"10.1093\/hmg\/ddy384","volume":"28","author":"P Zeng","year":"2019","unstructured":"Zeng P, Zhou X. Causal effects of blood lipids on amyotrophic lateral sclerosis: a Mendelian randomization study. Hum Mol Genet. 2019;28(4):688\u201397.","journal-title":"Hum Mol Genet"},{"issue":"4","key":"2442_CR32","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1002\/ana.25431","volume":"85","author":"S Bandres-Ciga","year":"2019","unstructured":"Bandres-Ciga S, Noyce AJ, Hemani G, Nicolas A, Calvo A, Mora G, et al. Shared polygenic risk and causal inferences in amyotrophic lateral sclerosis. Ann Neurol. 2019;85(4):470\u201381.","journal-title":"Ann Neurol"},{"issue":"1","key":"2442_CR33","doi-asserted-by":"publisher","first-page":"59","DOI":"10.2174\/1570159X15666170703101816","volume":"17","author":"A Fracassi","year":"2019","unstructured":"Fracassi A, Marangoni M, Rosso P, Pallottini V, Fioramonti M, Siteni S, et al. Statins and the brain: more than lipid lowering agents? Curr Neuropharmacol. 2019;17(1):59\u201383.","journal-title":"Curr Neuropharmacol"},{"issue":"2","key":"2442_CR34","doi-asserted-by":"publisher","first-page":"v","DOI":"10.1016\/j.yfrne.2009.04.006","volume":"30","author":"LM Garcia-Segura","year":"2009","unstructured":"Garcia-Segura LM, Balthazart J. Steroids and neuroprotection: new advances. Front Neuroendocrinol. 2009;30(2):v\u2013ix.","journal-title":"Front Neuroendocrinol"},{"issue":"2","key":"2442_CR35","first-page":"127","volume":"35","author":"M Liu","year":"2010","unstructured":"Liu M, Kelley MH, Herson PS, Hurn PD. Neuroprotection of sex steroids. Minerva Endocrinol. 2010;35(2):127\u201343.","journal-title":"Minerva Endocrinol"},{"issue":"2","key":"2442_CR36","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1016\/j.phrs.2011.12.001","volume":"65","author":"M Galbiati","year":"2012","unstructured":"Galbiati M, Onesto E, Zito A, Crippa V, Rusmini P, Mariotti R, et al. The anabolic\/androgenic steroid nandrolone exacerbates gene expression modifications induced by mutant SOD1 in muscles of mice models of amyotrophic lateral sclerosis. Pharmacol Res. 2012;65(2):221\u201330.","journal-title":"Pharmacol Res"},{"issue":"Suppl 1","key":"2442_CR37","doi-asserted-by":"publisher","first-page":"S94","DOI":"10.4103\/0976-500X.120975","volume":"4","author":"M Ciriaco","year":"2013","unstructured":"Ciriaco M, Ventrice P, Russo G, Scicchitano M, Mazzitello G, Scicchitano F, et al. Corticosteroid-related central nervous system side effects. J Pharmacol Pharmacother. 2013;4(Suppl 1):S94\u20138.","journal-title":"J Pharmacol Pharmacother"},{"key":"2442_CR38","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1016\/j.brainres.2016.12.029","volume":"1657","author":"RM Kassa","year":"2017","unstructured":"Kassa RM, Bonafede R, Boschi F, Bentivoglio M, Mariotti R. Effect of physical exercise and anabolic steroid treatment on spinal motoneurons and surrounding glia of wild-type and ALS mice. Brain Res. 2017;1657:269\u201378.","journal-title":"Brain Res"},{"issue":"5","key":"2442_CR39","doi-asserted-by":"publisher","first-page":"952","DOI":"10.1111\/j.1471-4159.2012.07771.x","volume":"122","author":"JH Shin","year":"2012","unstructured":"Shin JH, Lee YA, Lee JK, Lee YB, Cho W, Im DS, et al. Concurrent blockade of free radical and microsomal prostaglandin E synthase-1-mediated PGE2 production improves safety and efficacy in a mouse model of amyotrophic lateral sclerosis. J Neurochem. 2012;122(5):952\u201361.","journal-title":"J Neurochem"},{"issue":"2","key":"2442_CR40","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1111\/j.1600-0404.1990.tb01602.x","volume":"82","author":"L Werdelin","year":"1990","unstructured":"Werdelin L, Boysen G, Jensen TS, Mogensen P. Immunosuppressive treatment of patients with amyotrophic lateral sclerosis. Acta Neurol Scand. 1990;82(2):132\u20134.","journal-title":"Acta Neurol Scand"},{"issue":"3\u20134","key":"2442_CR41","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1080\/21678421.2017.1421666","volume":"19","author":"CN Fournier","year":"2018","unstructured":"Fournier CN, Schoenfeld D, Berry JD, Cudkowicz ME, Chan J, Quinn C, et al. An open label study of a novel immunosuppression intervention for the treatment of amyotrophic lateral sclerosis. Amyotroph Lateral Scler Frontotemporal Degener. 2018;19(3\u20134):242\u20139.","journal-title":"Amyotroph Lateral Scler Frontotemporal Degener"},{"issue":"7770","key":"2442_CR42","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1038\/s41586-019-1443-5","volume":"572","author":"E Blacher","year":"2019","unstructured":"Blacher E, Bashiardes S, Shapiro H, Rothschild D, Mor U, Dori-Bachash M, et al. Potential roles of gut microbiome and metabolites in modulating ALS in mice. Nature. 2019;572(7770):474\u201380.","journal-title":"Nature"},{"issue":"5","key":"2442_CR43","doi-asserted-by":"publisher","first-page":"784","DOI":"10.3390\/microorganisms8050784","volume":"8","author":"M Obrenovich","year":"2020","unstructured":"Obrenovich M, Jaworski H, Tadimalla T, Mistry A, Sykes L, Perry G, et al. The role of the microbiota-gut-brain axis and antibiotics in ALS and neurodegenerative diseases. Microorganisms. 2020;8(5):784.","journal-title":"Microorganisms"},{"issue":"5","key":"2442_CR44","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1016\/j.contraception.2006.12.022","volume":"75","author":"E Shortridge","year":"2007","unstructured":"Shortridge E, Miller K. Contraindications to oral contraceptive use among women in the United States, 1999\u20132001. Contraception. 2007;75(5):355\u201360.","journal-title":"Contraception"},{"issue":"435","key":"2442_CR45","first-page":"1657","volume":"48","author":"PC Hannaford","year":"1998","unstructured":"Hannaford PC, Kay CR. The risk of serious illness among oral contraceptive users: evidence from the RCGP\u2019s oral contraceptive study. Br J Gen Pract. 1998;48(435):1657\u201362.","journal-title":"Br J Gen Pract"},{"issue":"2","key":"2442_CR46","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1677\/JOE-10-0338","volume":"208","author":"A Das","year":"2011","unstructured":"Das A, Smith JA, Gibson C, Varma AK, Ray SK, Banik NL. Estrogen receptor agonists and estrogen attenuate TNF-\u03b1-induced apoptosis in VSC4.1 motoneurons. J Endocrinol. 2011;208(2):171\u201382.","journal-title":"J Endocrinol"},{"issue":"3","key":"2442_CR47","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1007\/s10571-013-9908-9","volume":"33","author":"A Cardona-Rossinyol","year":"2013","unstructured":"Cardona-Rossinyol A, Mir M, Caraballo-Miralles V, Llad\u00f3 J, Olmos G. Neuroprotective effects of estradiol on motoneurons in a model of rat spinal cord embryonic explants. Cell Mol Neurobiol. 2013;33(3):421\u201332.","journal-title":"Cell Mol Neurobiol"},{"issue":"11","key":"2442_CR48","doi-asserted-by":"publisher","first-page":"1436","DOI":"10.1111\/ene.12632","volume":"22","author":"D Mariosa","year":"2015","unstructured":"Mariosa D, Kamel F, Bellocco R, Ye W, Fang F. Association between diabetes and amyotrophic lateral sclerosis in Sweden. Eur J Neurol. 2015;22(11):1436\u201342.","journal-title":"Eur J Neurol"},{"issue":"1","key":"2442_CR49","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1186\/s12916-019-1448-9","volume":"17","author":"P Zeng","year":"2019","unstructured":"Zeng P, Wang T, Zheng J, Zhou X. Causal association of type 2 diabetes with amyotrophic lateral sclerosis: new evidence from Mendelian randomization using GWAS summary statistics. BMC Med. 2019;17(1):225.","journal-title":"BMC Med"},{"issue":"34","key":"2442_CR50","doi-asserted-by":"publisher","first-page":"7805","DOI":"10.1523\/JNEUROSCI.2038-05.2005","volume":"25","author":"B Sch\u00fctz","year":"2005","unstructured":"Sch\u00fctz B, Reimann J, Dumitrescu-Ozimek L, Kappes-Horn K, Landreth GE, Sch\u00fcrmann B, et al. The oral antidiabetic pioglitazone protects from neurodegeneration and amyotrophic lateral sclerosis-like symptoms in superoxide dismutase-G93A transgenic mice. J Neurosci. 2005;25(34):7805\u201312.","journal-title":"J Neurosci"},{"key":"2442_CR51","doi-asserted-by":"publisher","first-page":"153.e1","DOI":"10.1016\/j.neurobiolaging.2020.04.011","volume":"92","author":"D Schijven","year":"2020","unstructured":"Schijven D, Stevelink R, McCormack M, van Rheenen W, Luykx JJ, Koeleman BPC, et al. Analysis of shared common genetic risk between amyotrophic lateral sclerosis and epilepsy. Neurobiol Aging. 2020;92:153.e1-.e5.","journal-title":"Neurobiol Aging."},{"issue":"23","key":"2442_CR52","doi-asserted-by":"publisher","first-page":"5417","DOI":"10.1111\/bph.12857","volume":"171","author":"J Liang","year":"2014","unstructured":"Liang J, Chao D, Sandhu HK, Yu Y, Zhang L, Balboni G, et al. \u03b4-Opioid receptors up-regulate excitatory amino acid transporters in mouse astrocytes. Br J Pharmacol. 2014;171(23):5417\u201330.","journal-title":"Br J Pharmacol"},{"issue":"4","key":"2442_CR53","doi-asserted-by":"publisher","first-page":"527","DOI":"10.4161\/auto.5923","volume":"4","author":"F Fornai","year":"2008","unstructured":"Fornai F, Longone P, Ferrucci M, Lenzi P, Isidoro C, Ruggieri S, et al. Autophagy and amyotrophic lateral sclerosis: the multiple roles of lithium. Autophagy. 2008;4(4):527\u201330.","journal-title":"Autophagy"},{"issue":"18","key":"2442_CR54","doi-asserted-by":"publisher","first-page":"1915","DOI":"10.1212\/WNL.0000000000004606","volume":"89","author":"RPA van Eijk","year":"2017","unstructured":"van Eijk RPA, Jones AR, Sproviero W, Shatunov A, Shaw PJ, Leigh PN, et al. Meta-analysis of pharmacogenetic interactions in amyotrophic lateral sclerosis clinical trials. Neurology. 2017;89(18):1915\u201322.","journal-title":"Neurology"},{"issue":"5\u20136","key":"2442_CR55","doi-asserted-by":"publisher","first-page":"453","DOI":"10.3109\/21678421.2014.903974","volume":"15","author":"S Paganoni","year":"2014","unstructured":"Paganoni S, Macklin EA, Lee A, Murphy A, Chang J, Zipf A, et al. Diagnostic timelines and delays in diagnosing amyotrophic lateral sclerosis (ALS). Amyotroph Lateral Scler Frontotemporal Degener. 2014;15(5\u20136):453\u20136.","journal-title":"Amyotroph Lateral Scler Frontotemporal Degener"},{"issue":"1","key":"2442_CR56","doi-asserted-by":"crossref","first-page":"e12108","DOI":"10.1002\/trc2.12108","volume":"6","author":"G Torrandell-Haro","year":"2020","unstructured":"Torrandell-Haro G, Branigan GL, Vitali F, Geifman N, Zissimopoulos JM, Brinton RD. Statin therapy and risk of Alzheimer\u2019s and age-related neurodegenerative diseases. Alzheimers Dement (N Y). 2020;6(1):e12108.","journal-title":"Alzheimers Dement (N Y)"},{"issue":"1","key":"2442_CR57","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1186\/s12874-019-0695-y","volume":"19","author":"G Prada-Ramallal","year":"2019","unstructured":"Prada-Ramallal G, Takkouche B, Figueiras A. Bias in pharmacoepidemiologic studies using secondary health care databases: a scoping review. BMC Med Res Methodol. 2019;19(1):53.","journal-title":"BMC Med Res Methodol"},{"issue":"3","key":"2442_CR58","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1177\/2042098611404920","volume":"2","author":"L Wise","year":"2011","unstructured":"Wise L. Risks and benefits of (pharmaco)epidemiology. Ther Adv Drug Saf. 2011;2(3):95\u2013102.","journal-title":"Ther Adv Drug Saf"},{"issue":"7","key":"2442_CR59","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1007\/s40263-020-00728-2","volume":"34","author":"L Li","year":"2020","unstructured":"Li L, Sujan AC, Butwicka A, Chang Z, Cortese S, Quinn P, et al. Associations of prescribed ADHD medication in pregnancy with pregnancy-related and offspring outcomes: a systematic review. CNS Drugs. 2020;34(7):731\u201347.","journal-title":"CNS Drugs"},{"issue":"4","key":"2442_CR60","doi-asserted-by":"publisher","first-page":"1377","DOI":"10.1007\/s10072-021-05099-0","volume":"42","author":"R Vasta","year":"2021","unstructured":"Vasta R, D\u2019Ovidio F, Logroscino G, Chi\u00f2 A. The links between diabetes mellitus and amyotrophic lateral sclerosis. Neurol Sci. 2021;42(4):1377\u201387.","journal-title":"Neurol Sci"},{"key":"2442_CR61","doi-asserted-by":"publisher","unstructured":"Longinetti E, Sveinsson O, Press R, Ye W, Ingre C, Piehl F, Fang F. ALS patients with concurrent neuroinflammatory disorders; a nationwide clinical records study. Amyotroph Lateral Scler Frontotemporal Degener. 2022;23(3-4):209\u201319. https:\/\/doi.org\/10.1080\/21678421.2021.1946084. Epub 2021 Jul 10. PMID: 34852680.","DOI":"10.1080\/21678421.2021.1946084"},{"issue":"502","key":"2442_CR62","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1080\/01621459.2013.770705","volume":"108","author":"L Zhao","year":"2013","unstructured":"Zhao L, Tian L, Cai T, Claggett B, Wei LJ. Effectively selecting a target population for a future comparative study. J Am Stat Assoc. 2013;108(502):527\u201339.","journal-title":"J Am Stat Assoc"},{"issue":"7","key":"2442_CR63","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1038\/nrrheum.2015.30","volume":"11","author":"K Yoshida","year":"2015","unstructured":"Yoshida K, Solomon DH, Kim SC. Active-comparator design and new-user design in observational studies. Nat Rev Rheumatol. 2015;11(7):437\u201341.","journal-title":"Nat Rev Rheumatol"},{"issue":"3","key":"2442_CR64","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1080\/00273171.2011.568786","volume":"46","author":"PC Austin","year":"2011","unstructured":"Austin PC. An introduction to propensity score methods for reducing the effects of confounding in observational studies. Multivar Behav Res. 2011;46(3):399\u2013424.","journal-title":"Multivar Behav Res"},{"issue":"8","key":"2442_CR65","doi-asserted-by":"publisher","first-page":"998","DOI":"10.1513\/AnnalsATS.201903-241OC","volume":"16","author":"AJ Admon","year":"2019","unstructured":"Admon AJ, Donnelly JP, Casey JD, Janz DR, Russell DW, Joffe AM, et al. Emulating a novel clinical trial using existing observational data. Predicting results of the PreVent study. Ann Am Thorac Soc. 2019;16(8):998\u20131007.","journal-title":"Ann Am Thorac Soc"},{"issue":"4","key":"2442_CR66","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1080\/17482960802031092","volume":"9","author":"L Zinman","year":"2008","unstructured":"Zinman L, Sadeghi R, Gawel M, Patton D, Kiss A. Are statin medications safe in patients with ALS? Amyotroph Lateral Scler. 2008;9(4):223\u20138.","journal-title":"Amyotroph Lateral Scler"},{"issue":"4","key":"2442_CR67","doi-asserted-by":"publisher","first-page":"241","DOI":"10.3109\/21678421.2012.732078","volume":"14","author":"Z Zheng","year":"2013","unstructured":"Zheng Z, Sheng L, Shang H. Statins and amyotrophic lateral sclerosis: a systematic review and meta-analysis. Amyotroph Lateral Scler Frontotemporal Degener. 2013;14(4):241\u20135.","journal-title":"Amyotroph Lateral Scler Frontotemporal Degener"},{"issue":"6","key":"2442_CR68","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1080\/17482960802163614","volume":"9","author":"M Qureshi","year":"2008","unstructured":"Qureshi M, Shui A, Dibernardo AB, Brown RH Jr, Schoenfeld DA, Cudkowicz ME. Medications and laboratory parameters as prognostic factors in amyotrophic lateral sclerosis. Amyotroph Lateral Scler. 2008;9(6):369\u201374.","journal-title":"Amyotroph Lateral Scler"},{"issue":"6","key":"2442_CR69","doi-asserted-by":"publisher","first-page":"e37885","DOI":"10.1371\/journal.pone.0037885","volume":"7","author":"L Dupuis","year":"2012","unstructured":"Dupuis L, Dengler R, Heneka MT, Meyer T, Zierz S, Kassubek J, et al. A randomized, double blind, placebo-controlled trial of pioglitazone in combination with riluzole in amyotrophic lateral sclerosis. PLoS ONE. 2012;7(6):e37885.","journal-title":"PLoS ONE"}],"container-title":["BMC Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12916-022-02442-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12916-022-02442-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12916-022-02442-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,25]],"date-time":"2023-11-25T09:37:08Z","timestamp":1700905028000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcmedicine.biomedcentral.com\/articles\/10.1186\/s12916-022-02442-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8,5]]},"references-count":69,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["2442"],"URL":"https:\/\/doi.org\/10.1186\/s12916-022-02442-w","relation":{},"ISSN":["1741-7015"],"issn-type":[{"value":"1741-7015","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,8,5]]},"assertion":[{"value":"23 February 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 June 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 August 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"251"}}